ADAR1 Capital Management »

Protagonist Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Protagonist Therapeutics (PTGX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Protagonist Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Protagonist Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Protagonist Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $44M 981k 45.00
2024-06-30 $56M 1.6M 34.65
2024-03-31 $23M 786k 28.93
2023-12-31 $4.6M 201k 22.93

More positions owned by ADAR1 Capital Management

Cytokinetics Com New (CYTK)
Protagonist Therapeutics (PTGX)
Bridgebio Pharma (BBIO)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Immunovant (IMVT)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Ascendis Pharma A/s Sponsored Adr (ASND)
Zura Bio Class A Ord Shs (ZURA)
Zai Lab Adr (ZLAB)
Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Aa Mission Acquisition Corp Ord Shs Cl A (AAM)
Mineralys Therapeutics (MLYS)
Syndax Pharmaceuticals (SNDX)

View all positions for ADAR1 Capital Management

Top funds holding Protagonist Therapeutics

BlackRock
Farallon Capital Management
Rtw Investments
Vanguard Group
State Street Corporation
Johnson & Johnson
Pacer Advisors
BVF
Leucadia National Corporation
Geode Capital Management
Perceptive Advisors
T. Rowe Price Associates
Adage Capital Partners GP
ADAR1 Capital Management
Goldman Sachs Group

View all funds holding Protagonist Therapeutics